2009.04.30 Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes

Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese bio […]

2009.04.16 New Stem Cell Technology to Improve Drug Safety

iPS cardiomyocytes used in a novel cardiotoxicity assay Drug side effects are a major problem for the drug ind […]

  • «
  • 1
  • »